1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Bazedoxifene Acetate Tablets
Trade Name: VIVIANT; CONBRIZA
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for osteoporosis

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Skin Sensitization: Category 1
Reproductive Toxicity: Category 2

EU Classification:

EU Indication of danger: Toxic to Reproduction: Category 3
Irritant

EU Risk Phrases:
R62 - Possible risk of impaired fertility.
R43 - May cause sensitization by skin contact.

Label Elements

Signal Word: Warning
Hazard Statements:
H361f - Suspected of damaging fertility
H317 - May cause an allergic skin reaction
Precautionary Statements:

P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P363 - Wash contaminated clothing before reuse
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention

Other Hazards
Australian Hazard Classification (NOHSC):

Note:
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bazedoxifene Acetate</td>
<td>198481-33-3</td>
<td>Not Listed</td>
<td>N;R50/53 Repr Cat.3;R62 Xi,R43</td>
<td>Aquatic Acute 1;H400 Aquatic Chronic 1;H410 Repr.2;H361f Skin Sens. 1,H317</td>
<td>5-10</td>
</tr>
<tr>
<td>Silica colloidal, Ph. Eur.</td>
<td>112945-52-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Starch, pregelatinized</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium lauryl sulfate</td>
<td>151-21-3</td>
<td>205-788-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium Stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium starch glycolate</td>
<td>9063-38-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Ascorbic acid (Vitamin C)</td>
<td>50-81-7</td>
<td>200-066-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose NF, monohydrate</td>
<td>64044-51-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Water, purified</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Opadry white</td>
<td>NOT ASSIGNED</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Opadry clear</td>
<td>NOT ASSIGNED</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>
4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire. May include oxides of carbon and nitrogen

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Bazedoxifene Acetate
Pfizer OEL TWA-8 Hr: 1µg/m³, Sensitizer

Silica colloidal, Ph. Eur.
Austria OEL - MAKs 4 mg/m³

Starch, pregelatinized
ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Bulgaria OEL - TWA 10.0 mg/m³
Czech Republic OEL - TWA 4.0 mg/m³
Greece OEL - TWA 10 mg/m³
5 mg/m³
Ireland OEL - TWAs 10 mg/m³
4 mg/m³
OSHA - Final PELS - TWAs: 15 mg/m³
Portugal OEL - TWA 10 mg/m³
Slovakia OEL - TWA 4 mg/m³
Spain OEL - TWA 10 mg/m³
Switzerland OEL -TWAs 3 mg/m³

Microcrystalline cellulose
ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Estonia OEL - TWA 10 mg/m³
France OEL - TWA 10 mg/m³
Ireland OEL - TWAs 10 mg/m³
4 mg/m³
Latvia OEL - TWA 2 mg/m³
OSHA - Final PELS - TWAs: 15 mg/m³
Portugal OEL - TWA 10 mg/m³
Romania OEL - TWA 10 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Tablets
Odor: No data available.
Molecular Formula: Mixture

Color: White
Odor Threshold: No data available.
Molecular Weight: Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)

Bazedoxifene Acetate
Measured 7.8 Log P 4.98

Lactose NF, monohydrate
No data available

Microcrystalline cellulose
No data available

Sodium starch glycolate
No data available

Ascorbic acid (Vitamin C)
No data available

Magnesium Stearate
9. PHYSICAL AND CHEMICAL PROPERTIES

No data available

Water, purified
No data available

Opadry clear
No data available

Opadry white
No data available

Sodium lauryl sulfate
No data available

Starch, pregelatinized
No data available

Silica colloidal, Ph. Eur.
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

- Autoignition Temperature (Solid) (°C): No data available

- Flammability (Solids): No data available

- Flash Point (Liquid) (°C): No data available

- Upper Explosive Limits (Liquid) (% by Vol.): No data available

- Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

- Oxidizing Properties: No data available

- Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.

- Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

- Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Known Clinical Effects: Based on clinical trials in humans, possible adverse effects following exposure to this compound may include: back pain, decreased red blood cell count (anemia), headache, pain, respiratory infection, bronchial tube inflammation (bronchitis), urinary tract infection, allergic reaction, hives, redness and swelling of the skin (urticaria), insomnia, depression, palpitations, hot flashes, diarrhea, difficult digestion (dyspepsia), constipation, acid reflux, dry mouth, and flatulence.
11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Bazedoxifene Acetate
- Rat  Oral  LD 50  > 4000 mg/kg
- Mouse  Oral  LD 50  > 4000mg/kg

Microcrystalline cellulose
- Rat  Oral  LD 50  > 5000 mg/kg
- Rabbit  Dermal  LD 50  > 2000 mg/kg

Ascorbic acid (Vitamin C)
- Rat  Oral  LD 50  11.9 g/kg

Sodium lauryl sulfate
- Rat  Oral  LD 50  1288 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Bazedoxifene Acetate
- Skin Irritation  Rabbit  Non-irritating
- Skin Sensitization - LLNA  Mouse  Positive
- Eye Irritation (In vitro, REET)  Rabbit  Minimal
- Eye Irritation  Rabbit  Minimal

Microcrystalline cellulose
- Skin Irritation  Rabbit  Non-irritating
- Eye Irritation  Rabbit  Non-irritating

Sodium lauryl sulfate
- Eye Irritation  Rabbit  Moderate
- Skin Irritation  Rabbit  Mild Moderate
- Skin Sensitization - GPMT  Guinea Pig  Negative
- Skin Sensitization - LLNA  Mouse  Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Bazedoxifene Acetate
- 30 Day(s)  Rat  Oral  (F) 5 mg/kg/day  LOAEL  Female reproductive system
- 30 Day(s)  Non-human Primate  Oral  (M) 200 mg/kg/day  NOAEL  None identified
- 30 Day(s)  Non-human Primate  Oral  (F) 10 mg/kg/day  LOAEL  Female reproductive system
- 26 Week(s)  Rat  Oral  10 mg/kg/day  LOAEL  Skin, Female reproductive system, Mammary gland, Kidney
- 27 Week(s)  Non-human Primate  Oral  1 mg/kg/day  LOAEL  Female reproductive system

Magnesium Stearate
- 13 Week(s)  Rat  Oral  1092 g/kg  LOAEL  Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Bazedoxifene Acetate
- Reproductive & Fertility-Males  Rat  Oral  300 mg/kg/day  NOAEL  Fertility
11. TOXICOLOGICAL INFORMATION

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

- **Bazedoxifene Acetate**
  - Bacterial Mutagenicity (Ames)  
    - *Salmonella*, *E. coli*  
      - Negative
  - In Vitro Micronucleus  
    - Chinese Hamster Ovary (CHO) cells  
      - Negative
  - In Vivo Micronucleus  
    - Mouse Bone Marrow  
      - Negative
  - Mammalian Cell Mutagenicity  
    - Mouse Lymphoma  
      - Negative

- **Sodium lauryl sulfate**
  - Bacterial Mutagenicity (Ames)  
    - *Salmonella*  
      - Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

- **Bazedoxifene Acetate**
  - 2 Year(s)  
    - Rat  
      - Oral, in feed  
        - Benign tumors

- **Sodium lauryl sulfate**
  - Bacterial Mutagenicity (Ames)  
    - *Salmonella*  
      - Negative

- **Silica colloidal, Ph. Eur.**
  - IARC:  
    - Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:

- Releases to the environment should be avoided. The Drug Product Level data below is for a substantially similar mixture.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

- **Bazedoxifene Acetate**
  - *Selenastrum capricornutum* (Green Alga)  
    - OECD EC50  
      - 72 Hours  
        - 0.46 mg/L
  - *Pseudokirchneriella subcapitata* (Green Alga)  
    - OECD ErC50  
      - 72 Hours  
        - 0.095 mg/L
  - *Pimephales promelas* (Fathead Minnow)  
    - OECD LC50  
      - 96 Hours  
        - 1.77 mg/L
  - *Daphnia magna* (Water Flea)  
    - OECD LC50  
      - 48 Hours  
        - 6.28 mg/L
  - *Sodium lauryl sulfate*  
    - *Oncorhynchus mykiss* (Rainbow Trout)  
      - LC50  
        - 96 Hours  
          - 3.6 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

- **Bazedoxifene Acetate**
  - Activated sludge  
    - OECD EC50  
      - > 8.0 mg/L

Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

- **Bazedoxifene Acetate**
SAFETY DATA SHEET

Material Name: Bazedoxifene Acetate Tablets
Revision date: 10-Nov-2014

Pimephales promelas (Fathead Minnow) OECD 33 Day(s) NOEC 0.86 mg/L Survival
Daphnia magna (Water Flea) OECD 21 Day(s) NOEC 1.1 mg/L Reproduction
Daphnia magna (Water Flea) OECD 21 Day(s) EC50 1.8 mg/L Survival
Chironomus riparius (Midges) OECD 28 Day(s) NOEC 85 mg/kg Growth

Persistence and Degradability:
Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)
Bazedoxifene Acetate
OECD Activated sludge 0% After 28 Day(s) Not Ready

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Bazedoxifene Acetate
Measured 7.8 Log P 4.98

Mobility in Soil: No data available

Data for the Drug Product

Aquatic Toxicity

<table>
<thead>
<tr>
<th>Species</th>
<th>Method</th>
<th>End Point</th>
<th>Duration</th>
<th>Result (mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncorhynchus mykiss</td>
<td>OECD</td>
<td>LC50</td>
<td>96 Hours</td>
<td>&gt;100</td>
</tr>
<tr>
<td>(Rainbow Trout)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daphnia Magna (Water Flea)</td>
<td>ISO</td>
<td>EC50</td>
<td>48 Hours</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Pseudokirchneriella subcapitata (Green Alga)</td>
<td>ISO</td>
<td>IC50</td>
<td>72 Hours</td>
<td>&gt;100</td>
</tr>
</tbody>
</table>

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

PZ01848
15. REGULATORY INFORMATION

Canada - WHMIS: Classifications
WHMIS hazard class:
D2a  very toxic materials
D2b  toxic materials

<table>
<thead>
<tr>
<th>Material</th>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>California Proposition 65</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bazedoxifene Acetate</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Silica colloidal, Ph. Eur.</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
</tr>
<tr>
<td>Starch, pregelatinized</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Use restricted. See item 9[f], powder</td>
</tr>
<tr>
<td>Ascorbic acid (Vitamin C)</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
</tr>
</tbody>
</table>
### 15. REGULATORY INFORMATION

**REACH - Annex IV - Exemptions from the obligations of Register:**
- Present

**EU EINECS/ELINCS List**
- 200-066-2

**Sodium lauryl sulfate**
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 6
- EU EINECS/ELINCS List: 205-788-1

**Lactose NF, monohydrate**
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register: Present
- EU EINECS/ELINCS List: Not Listed

**Water, purified**
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register: Present
- EU EINECS/ELINCS List: 231-791-2

**Magnesium Stearate**
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 209-150-3

**Opadry white**
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- EU EINECS/ELINCS List: Not Listed

**Opadry clear**
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- EU EINECS/ELINCS List: Not Listed

### 16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3
Hazardous to the aquatic environment, acute toxicity-Cat.1; H400 - Very toxic to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects
Reproductive toxicity-Cat.2; H361f - Suspected of damaging fertility
Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

N - Dangerous for the environment
Toxic to Reproduction: Category 3
Xi - Irritant
R62 - Possible risk of impaired fertility.
R43 - May cause sensitization by skin contact.
R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 14 - Transport Information. Updated Section 2 - Hazard Identification.
Updated Section 12 - Ecological Information.

Revision date: 10-Nov-2014
Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet